Prince, 8, is handed a certificate confirming he is Ebola-free, outside an Ebola treatment center in Beni, DRC. Photo: Sally Hayden/SOPA Images/LightRocket via Getty Images

Public health officials announced Monday they had gathered enough preliminary data to determine that 2 of the 4 investigational treatments for Ebola performed better than the others. The current trial in the Democratic Republic of the Congo has been dropped to focus on a new extension trial for the 2 monoclonal antibodies.

Why it matters: There are currently no FDA-approved treatments for Ebola. Researchers testing drugs during the DRC's largest outbreak found a cocktail of 3 antibodies called REGN-EB3 was most effective, followed closely by monoclonal antibody 114.

"From now on, we will no longer have to say Ebola is untreatable [if caught early enough]."
— Jean-Jacques Muyembe-Tamfum, head of DRC's Ebola response, at press conference

Background: Four treatments — ZMapp, mAb114, remdesivir (GS-5734), and REGN-EB3 (REGN3470-3471-3479) — began undergoing randomized, controlled testing on Nov. 20 through an international research consortium arranged by the World Health Organization and co-led by the National Institute of Allergy and Infectious Disease.

What's new: NIAID director Anthony Fauci says the trial that ended Friday offered preliminary data showing mortality rates as follows: ZMapp at 49%, remdesivir at 53%, REGN-EB3 at 29%, and mAb114 was 34%. This compares with an estimated 67% overall mortality rate for untreated cases.

  • "The early stopping criteria [of the trial] was met by Regeneron [REGN-EB3]," Fauci said, when compared to the control, ZMapp.
  • Fauci warned that the numbers are still early: "More stringent data will be coming." For instance, roughly 15% of the participants in the study had received an experimental Ebola vaccine as well, and they aren't sure yet if that skewed the effect.
  • Both drugs block a particular component of the virus, Fauci added.
  • Regeneron Pharmaceuticals developed REGN-EB3 using mouse-generated antibodies that were then produced in specialized bioreactors. NIAID developed mAb114 from antibodies from an Ebola survivor, and granted a license to Ridgeback Biotherapeutics.

Meanwhile, as of Saturday, the WHO reported 2,816 cases (2,722 confirmed and 94 probable), including 1,888 deaths.

  • WHO's Mike Ryan, who was also at the press briefing, warned that although "the news today is fantastic," the complex scenario of insecurity and community distrust on the ground requires renewed efforts by the international security to offer help to the region.
  • "Too many people are not going to the Ebola Treatment Centers early enough," Ryan said, adding that he hopes the news will entice more people to come to ETCs earlier.
  • All ETCs will start offering both treatments.

Go deeper:

Editor's note: This piece was corrected to reflect the different ways the 2 treatments were developed (showing Regeneron did not use antibodies from an Ebola survivor).

Go deeper

Updated 59 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 9:45 p.m. ET: 19,282,972 — Total deaths: 718,851 — Total recoveries — 11,671,491Map.
  2. U.S.: Total confirmed cases as of 9:45 p.m. ET: 4,937,441 — Total deaths: 161,248 — Total recoveries: 1,623,870 — Total tests: 60,415,558Map.
  3. Politics: Trump says he's prepared to sign executive orders on coronavirus aid.
  4. Education: Cuomo says all New York schools can reopen for in-person learning.
  5. Public health: Surgeon general urges flu shots to prevent "double whammy" with coronavirus — Massachusetts pauses reopening after uptick in coronavirus cases.
  6. World: Africa records over 1 million coronavirus cases — Gates Foundation puts $150 million behind coronavirus vaccine production.

Warren and Clinton to speak on same night of Democratic convention

(Photos: Abdulhamid Hosbas/Anadolu Agency via Getty Images, Sean Rayford/Getty Images)

Sen. Elizabeth Warren and Hillary Clinton both are slated to speak on the Wednesday of the Democratic convention — Aug. 19 — four sources familiar with the planning told Axios.

Why it matters: That's the same night Joe Biden's running mate (to be revealed next week) will address the nation. Clinton and Warren represent two of the most influential wise-women of Democratic politics with the potential to turn out millions of establishment and progressive voters in November.

Trump considering order on pre-existing condition protections, which already exist

Photo: Jim Watson/AFP via Getty Images

President Trump announced on Friday he will pursue an executive order requiring insurance companies to cover pre-existing conditions, something that is already law.

Why it matters: The Affordable Care Act already requires insurers to cover pre-existing conditions. The Trump administration is currently arguing in a case before the Supreme Court to strike down that very law — including its pre-existing condition protections.